-
Impella 2.5: safe hemodynamic support in patients undergoing combined PCI and BAV
- 04/04/2019
- Posted by: Massimo Delle Donne
- Category: Cardiovascular
No CommentsThe Journal of Invasive Cardiology (J INVASIVE CARDIOL 2019;31[3]:52-56) publishes a prospective, non-randomized study about the safety and efficacy of elective use of hemodynamic support by the Impella 2.5 (Abiomed) in patients undergoing combined high-risk percutaneous coronary intervention (PCI) and balloon aortic valvuloplasty (BAV), as a bridge to transcatheter aortic valve replacement. The study was -
The impact of Neovasc Reducer on ischemic burden and myocardial perfusion: the JACC article
- 04/02/2019
- Posted by: Massimo Delle Donne
- Category: Cardiovascular, News
Neovasc, partner of GADA and leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that JACC Cardiovascular Interventions published a peer reviewed article on the impact of Neovasc Reducer on ischemic burden and myocardial perfusion. -
STEMI: a study published on Circulation confirms the efficiency of Impella CP on unloading the left ventricle
- 18/01/2019
- Posted by: Massimo Delle Donne
- Category: Cardiovascular, News
A new study published on Circulation (Circulation.2019;139:337–346. DOI: 10.1161/CIRCULATIONAHA.118.038269), the outcomes of which have been presented at the AHA congress by prof. Navin K. Kapur (Tufts Medical Center), confirms efficiency and safety of Abiomed Impella CP on unloading the left ventricle in patients presenting with anterior ST-segment elevation myocardial infarction (STEMI) without cardiogenic shock. Trial -
New partnership between GADA Italia and Lifetech Scientific Corporation
- 10/01/2019
- Posted by: Massimo Delle Donne
- Category: Cardiovascular, News
GADA Italia and Lifetech Scientific Corporation (LSC) have engaged with a long-time agreement for exclusive distribution over the whole national territory. LSC, established in 1999 in Shenzhen (People's Republic of China), is one of the most dynamic company in the development, production, and commercialization of minimally invasive interventional medical devices to treat cardiovascular diseases. Its -
Neovasc Reducer™: clinical results in microvascular angina
- 08/01/2019
- Posted by: Massimo Delle Donne
- Category: Cardiovascular, News
The Neovasc Reducer™ system is an implantable device, designed to create a permanent and controlled narrowing of the coronary sinus aimed at improving perfusion of ischemic regions in the myocardium in patients with reversible ischemic cardiomyopathy. The Reducer ™ is for use in patients, often defined "no options", who have refractory angina pectoris associated with -
The European experience of ACURATE neo in bicuspid and tricuspid aortic valves
- 17/12/2018
- Posted by: Massimo Delle Donne
- Category: Cardiovascular, News
The magazine EuroIntervention (EuroIntervention 2018; Jaa-467 2018, doi: 10.4244/EIJ-D-18-00281) publishes encouraging results about safety and feasibility of traetment of bicuspid aortic valves with the TAVI aortic valve ACURATE neo (Boston Scientific). The outcomes have been collected by a multicenter retrospective and not randomized study about European experience of ACURATE neo in bicuspid (BAV) and tricuspid -
Gada and Principia SGR announce a new partnership
- 30/10/2018
- Posted by: Massimo Delle Donne
- Category: News
Gada announces the entry of Principia, through the Principia III-Health fund, into the share capital. “In a context of growing competitiveness, this transaction reflects the value of our Group which, has steadily gained significant positions over the years in the distribution of medical devices and innovative services for Italian public and private hospitals“, commented Davide
-
VA ECMO-Impella Association: pulmonary flow improvement and effective left ventricular discharge
- 24/09/2018
- Posted by: Massimo Delle Donne
- Category: Cardiovascular, News
Asaio Journal magazine publishes an article on the improvement of pulmonary arterial flow that the Abiomed Impella ventricular support contributes to generating in patients undergoing ECMO veno-arterial treatment (VA ECMO). Abiomed Impella Impella devices are devices for temporary ventricular support. The areas of application are both protection during high-risk percutaneous coronary interventional procedures (PCI), circulatory -
1-Year Outcomes of the using of the ACURATE neo transcatheter heart valve in 1,000 Patients
- 13/09/2018
- Posted by: Massimo Delle Donne
- Category: Cardiovascular, News
The JACC-Cardiovascular Intervention published the 1-year outcomes of the perspective and multicentre SAVI-TF registry: in 25 European centers, 1000 patients are enrolled treated with transfemoral access by Boston Scientific's ACURATE neo valve (Logistic EuroSCORE II 6.6%). ACURATE neo ACURATE neo valve, composed of a self-expanding nitinol stent and porcine pericardial skirt, is designed in order -
BIOTRAC, healthcare traceability solution, has its web page
- 06/07/2018
- Posted by: Massimo Delle Donne
- Category: Blood and Infusion Management
BIOTRAC, the innovative solution for identification and traceability in the healthcare sector, has its web page. Developed by Gadamed, a GADA Group company, it uses RFID technology (acronym of Radio-Frequency IDentification), which through radio-frequency and the support of a "reader" is able to read, communicate and update the information stored in the “tag” memory of